PAVmed
PAVM
58 hedge funds and large institutions have $3.76M invested in PAVmed in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 9 closing their positions.
1,140% more call options, than puts
Call options by funds: $62K | Put options by funds: $5K
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
6% less funds holding
Funds holding: 62 → 58 (-4)
19% less capital invested
Capital invested by funds: $4.62M → $3.76M (-$869K)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
+$201K |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$129K |
| 3 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
+$14.1K |
| 4 |
LCS
Levin Capital Strategies
New York
|
+$9.47K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$57K |
| 2 |
Millennium Management
New York
|
-$49.3K |
| 3 |
AFG
Alterity Financial Group
Bangor,
Maine
|
-$32.6K |
| 4 |
GWS
Glassman Wealth Services
Vienna,
Virginia
|
-$16.7K |
| 5 |
Morgan Stanley
New York
|
-$15.4K |
PAVM Hedge Fund Activity: Q1 2023 in Review
58 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q1 2023, worth a combined $3.76M — down 19% from $4.62M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PAVM and 5 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 17 added.
The largest buyer was Ayrton Capital, opening a new position worth an estimated $201K. The largest seller was BlackRock, cutting an estimated $57K.
- 58 institutional investors held PAVmed (PAVM) as of Q1 2023, down from 62 in Q4 2022.
- Funds reported $3.76M of PAVmed stock for Q1 2023, down 19% quarter-over-quarter.
- 5 funds opened new PAVmed positions in Q1 2023 and 9 closed out, a net change of -4 holders.
- The largest PAVmed buyer in Q1 2023 was Ayrton Capital, an estimated $201K added.
- The largest PAVmed seller in Q1 2023 was BlackRock, an estimated $57K sold.
Based on aggregated 13F filings for Q1 2023.